Machine learning-derived identification of tumor-infiltrating immune cell-related signature for improving prognosis and immunotherapy responses in patients with skin cutaneous melanoma

[1] Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48

[2] Miller KD(2022)Skin cancer: primary, secondary, and tertiary prevention. Part I J Am Acad Dermatol 87 255-268

[3] Wagle NS(2021)Immune checkpoint inhibitors in melanoma Lancet (London, England) 398 1002-1014

[4] Jemal A(2022)European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment—update 2022 Eur J Cancer (Oxford, England: 1990) 170 256-284

[5] Perez M(2021)Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance Annu Rev Pathol 16 223-249

[6] Abisaad JA(2020)Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primers 6 38-4944

[7] Rojas KD(2017)PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison Clin Cancer Res 23 4938-2501

[8] Marchetti MA(2017)Tumor mutational burden and response rate to PD-1 inhibition N Engl J Med 377 2500-2907

[9] Jaimes N(2019)Durable clinical benefit in patients with advanced cutaneous melanoma after discontinuation of anti-PD-1 therapies due to immune-related adverse events J Oncol 2019 1856594-5249

[10] Carlino MS(2020)Impact of high tumor mutational burden in solid tumors and challenges for biomarker application Cancer Treat Rev 89 2769689-3367

[1] Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48

[2] Miller KD(2022)Skin cancer: primary, secondary, and tertiary prevention. Part I J Am Acad Dermatol 87 255-268

[3] Wagle NS(2021)Immune checkpoint inhibitors in melanoma Lancet (London, England) 398 1002-1014

[4] Jemal A(2022)European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment—update 2022 Eur J Cancer (Oxford, England: 1990) 170 256-284

[5] Perez M(2021)Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance Annu Rev Pathol 16 223-249

[6] Abisaad JA(2020)Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primers 6 38-4944

[7] Rojas KD(2017)PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison Clin Cancer Res 23 4938-2501

[8] Marchetti MA(2017)Tumor mutational burden and response rate to PD-1 inhibition N Engl J Med 377 2500-2907

[9] Jaimes N(2019)Durable clinical benefit in patients with advanced cutaneous melanoma after discontinuation of anti-PD-1 therapies due to immune-related adverse events J Oncol 2019 1856594-5249

[10] Carlino MS(2020)Impact of high tumor mutational burden in solid tumors and challenges for biomarker application Cancer Treat Rev 89 2769689-3367